RCS - ReNeuron Group plc - ReNeuron to present new data at Exosome conference

ReNeuronAnnouncement

22/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220922:nRSV1921Aa&default-theme=true

RNS Number : 1921A  ReNeuron Group plc  22 September 2022

 
ReNeuron Group plc

("ReNeuron" or the "Company")

 

ReNeuron to present new data at the Extracellular Vesicle-Based Therapeutic
Development Summit

Dr Randolph Corteling, Chief Scientific Officer invited as guest speaker

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived
exosomes technologies, announces that the Company will be attending the
Extracellular Vesicle-Based Therapeutic Development Summit from the 4-6
October in Boston, MA.

 

As part of the event, Dr Corteling will be presenting new data on ReNeuron's
customisable Exosomes delivery platform in the morning session on 6 October,
exploring the latest advancements of Extracellular Vesicle-Based ('EV') cargo
delivery. Dr Corteling's presentation entitled Targeted Delivery of
Therapeutic Payloads Using Engineered Stem Cell Exosome will commence at 10:00
EST.

 

The Extracellular Vesicle-Based Therapeutic Development Summit in Boston
brings together international experts from across the industry focusing on
accelerating the discovery, translation and large-scale manufacturing of
Exosomes and EV's, through a series of abstracts, presentations, panel
discussions and partnering/networking events. Further information on the event
can be found here: https://ev-based-therapeutics.com/
(https://ev-based-therapeutics.com/)

 

The presentation will be made available after the event on the Company's
website: https://www.reneuron.com/investors/presentations/
(https://www.reneuron.com/investors/presentations/)

 

 

 
ENDS

 

Contacts:

 

 ReNeuron                                      www.reneuron.com/investors (http://www.reneuron.com/investors)
 Catherine Isted, Chief Executive Officer      Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Walbrook PR (Media & Investor Relations)      +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus / Alice Woodings                 +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell derived Exosome Technologies
company, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Company has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Company has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPUAABUPPGWG